loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations
Open ICICI 3-in-1 Account

Sai Life Sciences Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Sai Life Science Ltd. 15 May 2026 18:29 PM
Result PDF

Q4FY26 & FY26 Result Announced for Sai Life Science Ltd.

Pharmaceuticals company Sai Life Science announced Q4FY26 & FY26 results

Consolidated Financial Highlights:

  • Revenue from operations for Q4FY26 stood at Rs 6,021.39 million, representing a growth of 3.91% YoY compared to Rs 5,795.07 million in Q4FY25, and an increase of 8.21% QoQ from Rs 5,564.64 million in Q3FY26.
  • Total Income for Q4FY26 was Rs 6,176.58 million, an increase of 4.85% YoY against Rs 5,891.06 million in Q4FY25, and a growth of 9.35% QoQ compared to Rs 5,648.44 million in Q3FY26.
  • Profit after tax (PAT) for Q4FY26 reached Rs 1,042.36 million, registering a growth of 18.09% YoY from Rs 882.69 million in Q4FY25, and a 3.85% QoQ increase from Rs 1,003.75 million in Q3FY26.
  • For the full year FY26, Revenue from operations was Rs 21,924.92 million, showcasing a strong growth of 29.38% YoY compared to Rs 16,945.70 million in FY25.
  • Total Income for FY26 stood at Rs 22,416.20 million, up 29.47% YoY from Rs 17,313.49 million in FY25.
  • Profit after tax (PAT) for FY26 more than doubled, surging by 105.08% YoY to Rs 3,489.10 million from Rs 1,701.32 million in FY25.

Standalone Financial Highlights:

  • Revenue from operations for Q4FY26 was Rs 5,943.40 million, up 4.82% YoY from Rs 5,670.06 million in Q4FY25, and an increase of 8.22% QoQ from Rs 5,491.79 million in Q3FY26.
  • Total Income for Q4FY26 reached Rs 6,100.85 million, growing 5.77% YoY against Rs 5,768.25 million in Q4FY25, and 9.41% QoQ from Rs 5,576.26 million in Q3FY26.
  • Profit after tax (PAT) for Q4FY26 stood at Rs 1,025.32 million, a 14.01% YoY increase from Rs 899.35 million in Q4FY25, and a 5.02% QoQ growth from Rs 976.30 million in Q3FY26.
  • For the full year FY26, Revenue from operations stood at Rs 21,532.26 million, up 31.13% YoY compared to Rs 16,420.48 million in FY25.
  • Total Income for FY26 was Rs 22,023.57 million, an increase of 31.14% YoY from Rs 16,793.83 million in FY25.
  • Profit after tax (PAT) for FY26 experienced substantial growth of 96.86% YoY, reaching Rs 3,414.81 million compared to Rs 1,734.62 million in FY25.

Business & Segment Highlights:

  • Segment Performance: The Group operates in a single business segment, which is providing "Contract Research, Development and Manufacturing Services (CRDMO)".
  • IPO Fund Utilization: The company successfully utilized 100% of its net IPO proceeds, which amounted to Rs 9,098.84 million. Of this, Rs 7,200.00 million was utilized for the repayment/prepayment of outstanding borrowings, and Rs 1,898.84 million was used for general corporate purposes.
  • Exceptional Items (Labour Codes Impact): Following the Government of India's notification of new Labour Codes, the company reassessed its employee benefits liability. While Q3FY26 saw a charge of Rs 82.93 million, a reassessment based on revised remuneration structures yielded a credit of Rs 2.92 million in Q4FY26. The net exceptional expense for FY26 stood at Rs 80.01 million.
  • ESOP Grant: During FY26, the Nomination and Remuneration Committee approved the grant of 205,000 employee stock options under the Sai Life Sciences Limited Management ESOP Scheme – 2018, effective 13 November 2025.

Krishna Kanumuri, Managing Director and CEO, Sai Life Sciences, said, “FY26 was an important year for Sai Life Sciences as we continued to deepen our relationships with global pharma customers, expand our integrated CRDMO capabilities, and invest for the next phase of growth. While the operating environment remains dynamic, we believe the long-term fundamentals of innovation-led outsourcing and supply chain diversification continue to remain strong, and we are well positioned to participate meaningfully in this opportunity."

Siva Chittor, Chief Financial Officer, Sai Life Sciences, added, “FY26 reflected strong execution across the business, supported by healthy growth in both revenues and EBITDA. As we enter the next phase of expansion, we remain focused on disciplined capital allocation, operational resilience, and investments that are closely aligned with customer demand and long-term strategic opportunities.

Result PDF

Result PDF

Pharmaceuticals company Sai Life Science announced Q3FY26 results

  • Revenue from Operations was Rs 556 crore for Q3FY26 compared to Rs 440 crore in Q3FY25, an increase of 27% driven by strong growth both in CRO and CDMO services.
  • EBITDA stood at Rs 191 crore for Q3FY26 compared to Rs 124 crore in Q3FY25, an increase of 54%.
  • PAT stood at Rs 100 crore for Q3FY26 compared to Rs 54 crore in Q3FY25, an increase of 86%.

Krishna Kanumuri, Managing Director & CEO, Sai Life Sciences, said: “Q3FY26 marked continued progress in building Sai Life Sciences into a science-led, globally relevant CRDMO. During the quarter, we strengthened our technology platforms through greater adoption of digital, AI-enabled and modern chemistry approaches, enhancing our ability to support increasingly complex programs for global innovator clients.

In parallel, we continued to build organizational depth by adding experienced scientific and leadership talent, ensuring our teams scale in step with our expanding capabilities. Our capacity expansion plans remain firmly on track, with manufacturing scale-up and process development infrastructure progressing in line with our long-term roadmap. These investments are being guided by the evolving scientific contours of next-generation medicines and the changing needs of our customers.

Looking ahead, we remain confident in sustaining our growth momentum in the coming year. With disciplined execution and a clear strategic direction, Sai Life Sciences is well positioned to support the next phase of innovation while creating long-term value for all stakeholders."

Siva Chittor, Chief Financial Officer, Sai Life Sciences, said: “We have delivered a robust growth in Q3FY26 which outperformed the broader CRDMO industry trend, with improved operating performance, driven by disciplined execution and healthy momentum across our businesses.

For the quarter, total revenue stood at Rs 556 crore, representing a 27% YoY increase, supported by sustained demand and healthy volume growth across key service lines. EBITDA grew by 54% year-on-year to Rs 191 crore, with margins expanding by 605 bps to 34%, supported by improved capacity utilization, operational efficiencies, and ongoing cost optimization initiatives.

As of date, we have invested Rs 405 crore in capital expenditure, aligned with our long-term strategy to strengthen capabilities and expand capacity. This investment remains in line with our guided FY26 capex plan and reinforces our commitment to building scalable, future-ready infrastructure.

We continue to focus on prudent capital allocation and margin discipline while investing selectively in areas that enhance our differentiated value proposition. With strengthened capabilities, a solid order pipeline, and a more resilient operating foundation, we are well positioned for another year of strong and profitable growth, creating enduring value for our stakeholders.”

Result PDF

Pharmaceuticals company Sai Life Science announced Q2FY26 results

  • Revenue from Operations was Rs 537 crore for Q2FY26 compared to Rs 396 crore in Q2FY25, an increase of 36% driven by strong growth both in CRO and CDMO services.
  • EBITDA stood at Rs 156 crore for Q2FY26 compared to Rs 109 crore in Q2FY25, an increase of 43%.
  • PAT stood at Rs 84 crore for Q2FY26 compared to Rs 42 crore in Q2FY25, an increase of 100%

Krishna Kanumuri, Managing Director & CEO, Sai Life Sciences, said: “We are pleased to report another strong quarter, supported by healthy demand across our discovery, development, and manufacturing services. The performance was driven by consistent execution, growing client relationships, and continued traction in late-stage and commercial programs.

As the industry evolves toward more complex and diversified science, we continue to invest in new modalities, advanced technologies, and capacity expansion to strengthen our long-term competitiveness. These investments are enabling us to address a broader range of client needs, enhance efficiency across the value chain, and build deeper scientific capabilities for the future.

Looking ahead, our priorities remain centered on scaling responsibly, advancing technology-led innovation, and deepening client collaborations. With a strong foundation, expanding infrastructure, and scientific excellence at the core of our strategy, Sai Life Sciences is well positioned to deliver sustainable growth and long-term value."

Siva Chittor, Whole-time Director & Chief Financial Officer, Sai Life Sciences, said: “We sustained our positive momentum this quarter, maintaining growth across our business and keeping Sai Life Sciences firmly on track toward its long-term aspirations.

Total revenue for Q2FY26 stood at Rs 537 crore, up 36% year-on-year, driven by healthy performance across both the CRO and CDMO services. EBITDA for the quarter was Rs 156 crore, with margins at 29%, supported by improved operating leverage, better utilization and continued cost discipline.

We incurred capex of Rs 248 crore during H1, primarily directed toward expanding our R&D capacity, and advancing our offerings in new modalities and technologies. These investments are aligned with our strategy to enhance scientific depth and build scalable capacity to support future growth.

We remain focused on maintaining financial discipline, driving margin improvement, and deploying capital effectively to sustain long-term, profitable growth.”

Result PDF

Pharmaceuticals company Sai Life Science announced Q1FY26 results

  • Revenue from Operations was Rs 496 crore for Q1FY26 compared to Rs 280 crore in Q1FY25, an increase of 77% driven primarily by strong growth in CDMO segment.
  • EBITDA stood at Rs 125 crore. for Q1FY26 compared to Rs 31 crore in Q1FY25. an increase of 305%.
  • EBITDA margin expanded by 14% YoY to 25% in Q1FY26.
  • PAT for Q1FY26 stood at Rs 60 crore.
  • Invested Rs 134 crore in capital expenditure during Q1FY26.

Krishna Kanumuri, Managing Director and CEO, Sai Life Sciences, said: “We have begun FY26 on a strong footing, delivering healthy performance across our Discovery, Development and Commercial Manufacturing businesses. This momentum reflects the growing trust and deepening engagement we share with our global pharma clients' relationships that continue to anchor us through macroeconomic uncertainty and broader industry cycles.

As the nature of innovation in drug development evolves, we are proactively investing in the infrastructure and scientific depth required to support complex and emerging modalities. During the quarter, we inaugurated new Biology Labs that significantly strengthen our Integrated Discovery platform and enhance our ability to handle greater molecular complexity. We also broke ground on a new Process R&D Block at our Hyderabad campus, which will nearly double our process R&D capacity and bring in next generation, data-rich process capabilities to handle increasingly complex molecules.

These are deliberate steps in our journey to be the partner of choice for advancing innovation in complex science. We remain committed to enabling our clients’ aspirations with speed, scientific rigor, and an unrelenting focus on quality."

Siva Chittor, Director and Chief Financial Officer, Sai Life Sciences, said:” We are pleased to report a robust performance for Q1FY26, marked by strong growth across our Discovery and CDMO businesses.

Total revenue for the quarter stood at Rs 496 crore, up 77% YoY, led by 113% growth in our CDMO segment and a 38% rise in Discovery revenues, enabled by deeper engagement with global clients.

We recorded EBITDA of Rs 125 crore, growing 305% YoY, with margins expanding to 25%, an improvement of 14% YoY driven by operating leverage, scale efficiencies, and improved productivity across our sites.

During the quarter, we invested Rs 134 crore in capex. This includes investments in new R&D infrastructure and process development capabilities, enabling us to support complex and emerging modalities such as peptides, ADCs, and oligonucleotides.

As we look ahead, we remain optimistic about our growth trajectory. With a strong foundation in place, we are focused on scaling execution, strengthening client partnerships, and investing in technology and talent to deliver sustained performance and long-term value.”

Result PDF

Pharmaceuticals company Sai Life Science announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Revenue from Operations was Rs 580 crore for Q4FY25 compared to Rs 439 crore in Q4FY24, an increase of 32%
  • EBITDA stood at Rs 161 crore. for Q4FY25 compared to Rs 124 crore. in Q4FY24, an increase of 30%
  • PAT stood at Rs 88 crore. for Q4FY25 compared to Rs 56 crore. in Q4FY24, an increase of 57%

FY25 Financial Highlights:

  • Revenue from Operations was Rs 1,695 crore for FY25 compared to Rs 1,465 crore in FY24, an increase of 16%
  • EBITDA stood at Rs 425 crore. for FY25 compared to Rs 300 crore in FY24. an increase of 42%
  • PAT stood at Rs 170crore. for FY25 compared to Rs 83 crore in FY24, an increase of 105%

Commenting on the performance during the quarter, Krishna Kanumuri, Managing Director and CEO, Sai Life Sciences, said, “We are pleased to report a strong performance for FY25, ably supported by solid execution, capacity expansion, and deeper engagement with our customers. Our integrated CRDMO model continues to add value, helping us deliver seamless solutions across the drug development lifecycle to our global and biotech partners.

One of the highlights of the year was the launch of our Peptide Research Centre, set up to meet the growing demand for complex peptide synthesis and conjugation. This investment marks another step forward in strengthening our capabilities to support next-generation therapeutics.

With India emerging as a strategic hub in global drug development, Sai Life Sciences is well-positioned to tap into new growth opportunities. We remain focused on investing in technology, infrastructure, and talent to stay aligned with the evolving needs of our clients.

As we step into FY26, our priorities remain clear - to expand our capabilities, improve execution, and deliver lasting value to our stakeholders.”

Siva Chittor, Director and Chief Financial Officer, Sai Life Sciences added, ” We are pleased to report a strong FY25 performance, driven by consistent momentum across our CDMO and CRO segments. Revenue grew by 16% and our EBITDA margin expanded to 25%, in line with our growth aspirations. Profit after tax grew by 105%, supported by stable finance costs and operating leverage. With the completion of our planned Rs 720 crore debt repayment, we have significantly strengthened our balance sheet and expect lower interest costs starting FY26.

Capex for the year stood at Rs 408 crore, focused on enhancing our manufacturing footprint and expanding discovery capabilities.

We remain committed to disciplined execution and prudent capital allocation as we continue to build on our growth momentum and deliver long-term value to stakeholders.”

Result PDF

Pharmaceuticals company Sai Life Science announced Q3FY25 results

  • Revenue from Operations was Rs 439.8 crore for Q3FY25 compared to Rs 383.6 crore in Q3FY24, an increase of 14.6%.
  • EBITDA stood at Rs 124.5 crore for Q3FY25 compared to Rs 104.2 crore in Q3FY24 an increase of 19.5%.
  • PAT stood at Rs 53.9 crore for Q3FY25 compared to Rs 39.6 crore in Q3FY24, an increase of 36.0%.

Krishna Kanumuri, Managing Director & CEO, Sai Life Sciences, said: “We are pleased to announce a healthy performance this quarter, driven by strong execution, expanding capacity, and deepening customer relationships. Our integrated CRDMO model continues to differentiate us in the market, enabling us to provide seamless solutions across the drug development lifecycle. The pharmaceutical and biotech industries are increasingly seeking partners with end-to-end capabilities, scientific excellence, and a commitment to speed and efficiency areas where Sai Life Sciences has built a strong competitive edge.

The global CRDMO industry presents a tremendous growth opportunity, particularly as large pharmaceutical and biotech companies diversify their supply chains and seek strategic partners beyond China. India is at the forefront of this transformation, with the potential to scale as a global innovation hub. With a robust pipeline of commercial molecules, a growing presence in key global markets, and continuous investments in technology and infrastructure, Sai Life Sciences is well-positioned to capitalize on these industry tailwinds.

As we look ahead, we remain focused on strengthening our service offerings, expanding our capabilities into new modalities, and driving operational excellence. Our unwavering commitment to innovation, quality, and customercentricity will continue to propel us forward, delivering sustainable value to all our stakeholders.”

Siva Chittor, Chief Financial Officer, Sai Life Sciences, said:” We are delighted to share our Q3 FY25 financial performance, which highlights robust business momentum, operational discipline, and strong customer relationships.

Revenue from operations grew to Rs 439.8 crore, up 15% from Rs 383.6 crore in Q3FY24, on account of continued momentum in both our CDMO and CRO businesses. Our EBITDA margin increased to 28.3% in Q3FY25, up from 27.5% in Q3FY24, reflecting improved operating leverage and enhanced productivity. PAT grew to Rs 53.9 crore, compared to Rs 39.6 crore in Q3FY24, highlighting that our operational strategies are delivering results and positioning the company for sustained financial strength.

This success is driven by disciplined cost management despite rising employee costs in line with our ongoing investment in talent and organizational growth. Finance costs remained relatively stable at Rs 23.1 crore for Q3FY25, compared to Rs 23.3 crore in the same quarter last year, indicating effective debt management. As of December 2024, the Company had repaid Rs 585.7 crore of debt out of the planned Rs 720.0 crore from the IPO proceeds. The remaining debt was repaid in January, and we expect a reduction in interest costs in the following quarter. We remain focused on investing in digital initiatives, new technologies, and commercial capabilities to fuel future growth.

Over the past five years, our strategic investments in talent, technology, and infrastructure have strengthened our position as a leading integrated CRDMO player. These investments are now translating into higher customer retention, an expanding product pipeline, and improving profitability.

Looking ahead, we expect sustained growth momentum, supported by a strong order pipeline and ongoing investments in infrastructure and capabilities.”

Result PDF

Trending News

BEL bags ₹608 cr orders from Defence Ministry for communication and electronic systems

BEL has secured additional orders worth ₹608 crore from the Ministry of Defence. 

Published on 26-May-2026 09:10

Amara Raja Q4 PAT spikes 93% to ₹322 cr on insurance gain; FY26 sales up 9% to ₹13,549 cr

On standalone basis, net sales for the quarter came in at ₹ 3,460 crore, up 16% YoY. EBITDA in Q4FY26 came in at ₹ 377 crore with corresponding EBITDA margins at 10.9%, down ~30 bps QoQ. 

Published on 26-May-2026 09:09

Ashok Leyland bags order for 715 vehicles from VRL Logistics; 300 units already delivered

In a press release, Ashok Leyland announced that it has secured an order for 715 vehicles from VRL Logistics, further strengthening their decades-long partnership. 

Published on 26-May-2026 09:08

Cyient Semiconductors raises $30m led by Edelweiss funds at a $500m valuation

Cyient Limited announced that its subsidiary, Cyient Semiconductors, has secured a strategic financing transaction led by Edelweiss-managed funds at a post-money equity valuation of ~ US$500 million (~ ₹4,600 crore). 

Published on 26-May-2026 09:07

Sudarshan Chemicals Q4 revenue surges 33% QoQ to ₹2,790 cr; net profit hits ₹82.5 cr

Sudarshan Chemicals in Q4FY26 reported revenues of ₹2,790 crore, up 33% QoQ The pigment business (96% of revenues) reported revenues of ₹2,689 crore, up 31% QoQ. 

Published on 26-May-2026 09:06

Brigade Enterprises signs JDA for ₹850-crore residential project in Kompally, Hyderabad

Brigade Enterprises has secured a Joint Development Agreement (JDA) to develop a project spread across 5.6 acres having estimated gross development value (GDV) of ₹850 crore at Kompally, Hyderabad.

Published on 26-May-2026 09:05

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app